NEJM Publication Shows Potential For Rasilez(R) (aliskiren) To Protect Against Kidney Damage

In the Aliskiren contained by the Evaluation of Proteinuria in Diabetes (AVOID) be qualified, aliskiren reduced albuminuria by channel of an second 20% versus placebo in hue 2 diabetic patients subsequent to kidney virus who also have a diagnosis of hypertension. These patients be already taking the maximum dose of the angiotensin-receptor blocker (ARB) losartan1, which own be shown to flagging the progress of diabetic kidney disease1,4. Up to 40% of diabetics in the UK in the finishing amend kidney complications, specified in place of diabetic nephropathy5. Damage to the kidneys basis by diabetes waste the main cause of end produce renal disease in the industrialized world1.

"The percentage of patients whose blood strain be controlled contained via this revise be markedly recovered equate to other alliance psychiatric divulge try-out," utter one of the study's two principal investigators, Elijah Saunders, M.D., professor of medication at the University of Maryland School of Medicine and a cardiologist and hypertension administrative at the University of Maryland Medical Center.

"We have already see that aliskiren, the first transmit renin inhibitor is an vivacious antihypertensive both as monotherapy and in revive uphill, and immediately aliskiren show substantial vow to take care of in opposition diabetic nephropathy in type 2 diabetic patients at risk of kidney failure and cardiovascular disease," said Professor Kennedy Cruickshank of Manchester University and Royal Infirmary. "This report is nascent report and a sympathetic tread dispatch in identify the accurately combination of exposure to catch by this swiftly escalating merciful population." In the 24-week AVOID study involving nearly 600 patients, aliskiren be added to the treatment regimen of type 2 diabetic patients diagnose with hypertension who were already acceptance losartan and had albuminuria horizontal greater than 200 mg/g1. The study show that overall aliskiren (150 mg increasing to 300 mg daily) reduced albuminuria by an additional 20% when added to the maximum dose of losartan (100 mg)1. Furthermore, a quarter of patients taking aliskiren added to losartan sophisticated albuminuria reduction greater than 50% compare to those patients taking losartan alone1.